PegIFN alfa-2b and NUC

Phase 3Small molecule

HHuashan Hospital

PegIFN alfa-2b and NUC is one of 6 small molecule programs targeting Withdrawal. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

WithdrawalNot yet recruiting

WithdrawalPhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Withdrawal

#DrugCompanyPhaseTrials

Pitocin

RRetrophin

Phase 2

1 2

PegIFN alfa-2b and NUC

HHuashan Hospital

Phase 3

1 3

Depacon

AbbVie

Preclinical

2 4

Nicotine Lozenge

FFertin Pharma A/S

Preclinical

1 5

Oestrogen

Novo Nordisk

Preclinical

1 6

Withdrawal

MMcGill University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Post-ApprovalNot yet recruiting

Withdrawal

NCT06900166

Clinical

Trials by Indication[1]

Withdrawal1 trial

Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg

Not yet recruiting·HHuashan Hospital·Phase 4·NCT06900166·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PegIFN alfa-2b and NUC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PegIFN alfa-2b and NUC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PegIFN alfa-2b and NUC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huashan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHuashan Hospital

PegIFN alfa-2b and NUC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Withdrawal1 trial

References

Drug Info

Quick Facts

Related News